Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss ... Zepbound sales reached $1.9 billion in the fourth quarter of 2024, compared with $176 million during the same period in 2023 — when it ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

Katherine Wolkoff for The New York Times Supported by By Lisa Miller Lisa Miller interviewed more than two dozen people about the effects weight-loss ... took her first dose of Zepbound on March ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.